Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Tamsulosin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA1A known ✓ | P35348 | 10/20 | 0.98 |
| ▸ | ADRA1D known ✓ | P25100 | 9/20 | 0.98 |
| ▸ | ADRA1B known ✓ | P35368 | 9/20 | 0.98 |
| ▸ | ADRB2 | P07550 | 4/20 | 0.98 |
| ▸ | ADRB1 | P08588 | 2/20 | 0.98 |
| ▸ | HTR1A | P08908 | 2/20 | 0.98 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.98 |
| ▸ | DRD2 | P14416 | 2/20 | 0.98 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.98 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.98 |
| ▸ | HTR2A | P28223 | 2/20 | 0.98 |
| ▸ | DRD3 | P35462 | 2/20 | 0.98 |
| ▸ | HTR2B | P41595 | 2/20 | 0.98 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.98 |
| ▸ | HTR7 | P34969 | 1/20 | 0.98 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.98 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.52 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.43 |
| ▸ | HRH1 | P35367 | 1/20 | 0.43 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tamsulosin SCHEMBL29641643 | 1.00 | ADRA1A (0.98) | ADRA1AADRA1DADRA1BADRB2ADRB1 | |
| Tamsulosin SCHEMBL3397438 | 1.00 | ADRA1A (0.98) | ADRA1AADRA1DADRA1BADRB2ADRB1 | |
| Tamsulosin SCHEMBL2319987 | 1.00 | ADRA1A (0.98) | ADRA1AADRA1DADRA1BADRB2ADRB1 | |
| Tamsulosin SCHEMBL29625170 | 1.00 | ADRA1A (0.98) | ADRA1AADRA1DADRA1BADRB2ADRB1 | |
| Tamsulosin SCHEMBL1560198 | 1.00 | ADRA1A (0.98) | ADRA1AADRA1DADRA1BADRB2ADRB1 | |
| Tamsulosin SCHEMBL2315085 | 1.00 | ADRA1A (0.98) | ADRA1AADRA1DADRA1BADRB2ADRB1 | |
| Tamsulosin SCHEMBL23428 | 1.00 | ADRA1A (0.98) | ADRA1AADRA1DADRA1BADRB2ADRB1 | |
| Tamsulosin SCHEMBL9300408 | 1.00 | ADRA1A (0.98) | ADRA1AADRA1DADRA1BADRB2ADRB1 | |
| Tamsulosin SCHEMBL356385 | 0.99 | ADRA1A (0.96) | ADRA1AADRA1DADRA1BADRB2ADRB1 | |
| Tamsulosin SCHEMBL11815414 | 0.99 | ADRA1A (0.96) | ADRA1AADRA1DADRA1BADRB2ADRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240216584-A1 | METHODS, SYSTEMS, AND DEVICES FOR GENERATING DEFINED FIBER CONSTRUCTS | NATIONAL INSTITUTES OF HEALTH | 2024-07-04 | — | — | US | disclosed |
| US-20230330157-A1 | MODULATION OF MICROBIOTA FUNCTION BY GENE THERAPY OF THE MICROBIOME TO PREVENT, TREAT OR CURE MICROBIOME-ASSOCIATED DISEASES OR DISORDERS | ELIGO BIOSCIENCE (FR) | 2023-10-19 | — | — | US | disclosed |
| US-11690880-B2 | Modulation of microbiota function by gene therapy of the microbiome to prevent, treat or cure microbiome-associated diseases or disorders | ELIGO BIOSCIENCE (FR) | 2023-07-04 | — | — | US | disclosed |
| US-20230126159-A1 | ENGINEERED BACTERIAL STRAINS COMPRISING A TRANSGENE | ELIGO BIOSCIENCE (FR) | 2023-04-27 | — | — | US | disclosed |
| WO-2023057598-A1 | METHODS INVOLVING BACTERIAL STRAIN REPLACEMENT | ELIGO BIOSCIENCE (FR) | 2023-04-13 | — | — | WO | disclosed |
| US-20230113800-A1 | MODULATION OF MICROBIOTA FUNCTION BY GENE THERAPY OF THE MICROBIOME TO PREVENT, TREAT OR CURE MICROBIOME-ASSOCIATED DISEASES OR DISORDERS | ELIGO BIOSCIENCE (FR) | 2023-04-13 | — | — | US | disclosed |
| US-20230114520-A1 | ENGINEERED BIFIDOBACTERIUM STRAINS COMPRISING A TRANSGENE | ELIGO BIOSCIENCE (FR) | 2023-04-13 | — | — | US | disclosed |
| US-11534467-B2 | Modulation of microbiota function by gene therapy of the microbiome to prevent, treat or cure microbiome-associated diseases or disorders | ELIGO BIOSCIENCE (FR) | 2022-12-27 | — | — | US | disclosed |
| WO-2021204967-A9 | MODULATION OF MICROBIOTA FUNCTION BY GENE THERAPY OF THE MICROBIOME TO PREVENT, TREAT OR CURE MICROBIOME-ASSOCIATED DISEASES OR DISORDERS | ELIGO BIOSCIENCE (FR) | 2022-11-10 | — | — | WO | disclosed |
| EP-4069840-A1 | MODULATION OF MICROBIOTA FUNCTION BY GENE THERAPY OF THE MICROBIOME TO PREVENT, TREAT OR CURE MICROBIOME-ASSOCIATED DISEASES OR DISORDERS | Eligo Bioscience (FR) | 2022-10-12 | — | — | EP | disclosed |
| WO-2022192517-A1 | METHODS, SYSTEMS, AND DEVICES FOR GENERATING DEFINED FIBER CONSTRUCTS | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2022-09-15 | — | — | WO | disclosed |
| US-20220233610-A1 | MODULATION OF MICROBIOTA FUNCTION BY GENE THERAPY OF THE MICROBIOME TO PREVENT, TREAT OR CURE MICROBIOME-ASSOCIATED DISEASES OR DISORDERS | ELIGO BIOSCIENCE (FR) | 2022-07-28 | — | — | US | disclosed |